Corporate firm handles cross-border acquisition

Chinese drugmaker buys majority of ASX-listed SG-based biopharma firm

Corporate firm handles cross-border acquisition

Thomson Geer handled the Australian elements for both parties of a complex cross-border acquisition.

Yifan Pharmaceutical has agreed to buy a majority stake in SciGen, with the aim to eventually bring the ASX-listed Singapore-based biopharmaceutical firm private. Yifan announced earlier this year that it has signed a binding offer with SciGen’s controlling shareholder, Warsaw-listed Bioton SA.

Thomson Geer said that the deal was valued at $28m.

The deal boosts Yifan’s research and production capacity of insulin products as diabetes becomes an increasingly large problem in China. Yifan gains SciGen’s product portfolio, which includes insulin, and its extensive sales network across more than 20 countries and regions, which includes the Asia-Pacific.

Partner Tim Flahvin and senior associate Venks Ananthakrishnan led the Thomson Geer team.

Tim Flahvin and Venks Ananthakrishnan

Related stories

Free newsletter

Subscribe to our FREE newsletter service and we’ll keep you up-to-date with the latest breaking news, cutting edge opinion, and expert analysis affecting both your business and the industry as whole.

Please enter your email address below and click on Sign Up for daily newsletters from Australasian Lawyer.

Recent articles & video

Lander & Rogers beefs up technology and digital practice with new partner

MinterEllison comments on litigation funder regulations

New Jersey Supreme Court boots judge for misconduct

COVID-19 and Australian courts and legal bodies updates: 1 June

KWM helps industrial chemicals manufacturer cook up $600m in capital raising under COVID-19

New Hong Kong security law an “unconscionable” threat to judicial independence, says IBA

Most Read Articles

Clayton Utz senior associate applauds greater focus on diversity and inclusion

HSF pumps up global financial services regulatory team with new partner

G+T helps newly-listed maltster brew up first capital raising with “novel relief” from ASIC

Ashurst helps challenger bank gain unicorn status on $230m capital raising